Call Us: US - +1 845 478 5244 | UK - +44 20 7193 7850 | AUS - +61 2 8005 4826

standard-of-care chemotherapy

The Zhou Laboratory studies how to combine standard-of-care chemotherapy and novel immunotherapy in a synergistic manner to treat cancer. Currently, chemotherapy is a major treatment modality for many types of cancer. However, chemotherapy is rarely curative. With recent advances in immune-based therapeutic strategies, there is growing interest in combining immunotherapy with conventional chemotherapy to achieve durable antitumor effects. Dr. Zhou’s group reported that melphalan, an alkylating agent commonly used in treating hematologic malignancy such as multiple myeloma, has immunostimulatory effects as reflected by its ability to induce immunogenic tumor cell death. The combination of melphalan and adoptive T cell therapy can mediate a better antitumor effect than either treatment alone (J Immunol. 2015, 194(4):2011-21). Dr. Zhou participated in a collaborative study with scientists at Zhongshan Medical University in China, which revealed the tumor suppressor function of Vps4A in heptoma cells (Hepatology. 2015, 61(4):1284-94). In addition, Dr. Zhou collaborated with GRU Cancer Center colleagues, Drs. Chunhong Yan and Kebin Liu, to investigate the stress response and myeloid cell differentiation (Nat Commun. 2015, 6:6752; J Immunol. 2015, 194(5):2369-79). Dr. Zhou also contributed to a study conducted by Dr. Lieping Chen’s group at Yale University investigating the role of B7-H3 in autoimmune disease and inflammation (PLoS One. 2015, 10(6)).